Genmab A (GMAB) Net Income towards Common Stockholders (2023 - 2026)
Genmab A (GMAB) recorded Net Income towards Common Stockholders of $303 million in the quarter ended Jun 30, 2026, up 471.7% from the prior quarter.
Powered by 
Analysis
Genmab A (GMAB) Net Income towards Common Stockholders (2023 - 2026) Analysis & Trends
On a TTM basis, Genmab A's Net Income towards Common Stockholders came in at $1.82 billion as of Jun 30, 2026; for the year ended Dec 31, 2025, it came in at $963 million, up 31.9% from the prior year.
- Annual Net Income towards Common Stockholders has a five-year compound annual growth rate of 19.7% (years ended Dec 2020 to Dec 2025).
- Across earlier years, Net Income towards Common Stockholders came in at $729.82 million in the year ended Dec 31, 2024 (+77.7%), $410.72 million in the year ended Dec 31, 2023 (-19.3%), $508.77 million in the year ended Dec 31, 2022 (+49.7%) and $339.89 million in the year ended Dec 31, 2021 (-13.2%).
- Quarterly Net Income towards Common Stockholders has ranged from -$3.81 billion in the quarter ended Dec 31, 2023 to $932 million in the quarter ended Sep 30, 2025 over the past five years.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,199.50 Bn | 1,168.08 Bn | 19.71 Bn | 7.10 Bn |
| 2 | Johnson & Johnson | 635.17 Bn | 555.03 Bn | 17.30 Bn | 210.00 Mn |
| 3 | AbbVie | 504.69 Bn | 477.85 Bn | 12.70 Bn | 3.61 Bn |
| 4 | Merck | 358.43 Bn | 312.86 Bn | 12.21 Bn | -1.34 Bn |
| 5 | Novartis Ag | 288.36 Bn | 252.75 Bn | 11.24 Bn | 3.26 Bn |
| 6 | Astrazeneca | 265.78 Bn | 239.54 Bn | 12.86 Bn | 2.51 Bn |
| 7 | Amgen | 237.46 Bn | 192.86 Bn | 7.24 Bn | 2.38 Bn |
| 8 | Gilead Sciences | 193.65 Bn | 167.76 Bn | 6.22 Bn | -10.50 Bn |
| 9 | Pfizer | 171.05 Bn | 118.00 Bn | 10.94 Bn | -248.00 Mn |
| 10 | Genmab A | 2.81 Bn | -2.56 Bn | 1.07 Bn | 246.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 246.00 Mn |
| Mar 31, 2026 | -106.00 Mn |
| Sep 30, 2025 | 407.00 Mn |
| Jun 30, 2025 | 339.00 Mn |
| Mar 31, 2025 | 208.00 Mn |
| Sep 30, 2024 | 315.00 Mn |
| Jun 30, 2024 | 173.00 Mn |
| Mar 31, 2024 | 199.00 Mn |
| Dec 31, 2023 | -2.92 Bn |
| Sep 30, 2023 | 2.13 Bn |
| Mar 31, 2023 | 266.00 Mn |
API Access
Genmab A Net Income towards Common Stockholders API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=GMAB&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-income-towards-common-stockholders", "ticker": "GMAB", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-income-towards-common-stockholders&ticker=GMAB&period=max&api_key=YOUR_API_KEY");
const data = await res.json();